Aimwell Partners Inc. reports company developments centered on AimwellBio, its healthcare and biopharmaceutical intelligence business. Recurring announcements cover the rollout of AIMWELL Cortex, the Federated Health Intelligence Network, source-traceable signal monitoring, confidence scoring, and verification processes designed for clinical, research, regulatory, and biopharma users.
Company news also describes demonstrations, onboarding activity, founding cohort development, live signal intelligence features, and engagement with clinicians, researchers, hospital systems, physician networks, and strategic advisors. The updates frame AimwellBio's work around healthcare RegTech, AI-output verification, clinical information validation, and structured intelligence mapping.
Aimwell Partners (OTC:AIMN), parent of AimwellBio, announced it has reached an agreement in principle to acquire a portfolio of intellectual property valued at approximately $10 million. The proposed deal is subject to due diligence, negotiation and execution of definitive agreements, approvals by all parties, and legal review, and may not be completed on the contemplated terms or at all.
The company said the intellectual property is expected to strengthen AimwellBio's long-term strategic position and support its mission of providing trusted, verified intelligence infrastructure for healthcare and life sciences. Aimwell will withhold details on the assets and transaction terms until closing, after which it plans to share comprehensive information on the acquired assets, their strategic importance, and planned integration into its platform, while continuing to provide updates in line with disclosure requirements.
Aimwell Partners (OTCID:AIMN), through its subsidiary AimwellBio, is developing the Federated Health Intelligence Network (FHIN), a credentialed network that links physicians, scientists, researchers and healthcare professionals with organizations seeking trusted healthcare insights.
The FHIN is designed to move beyond anonymous, AI‑generated or decontextualized content by highlighting identifiable experts, their credentials and the evidence behind their views. AimwellBio plans to feature selected contributors through profiles, interviews and expert commentary, emphasizing source traceability and professional judgment over raw data volume. The company is actively inviting qualified healthcare professionals to apply for inclusion, aiming to create a compounding ecosystem where trusted people, not just information, define the value of healthcare intelligence.
Aimwell Partners (OTC: AIMN), parent of AimwellBio, announced that effective immediately its Observer-tier access to the AimwellBio decision intelligence platform is available at no cost to credentialed biopharma professionals, including physicians, clinical researchers, and regulatory specialists. Verified credentials are the only requirement.
Simultaneously, the company published the Adversarial Validation Standard, v1, an open methodology detailing how intelligence signals are sourced, adversarially challenged, validated, confidence-scored, and cleared for publication, including when human review is required. Observer access also serves as the entry point to AimwellBio’s Federated Health Intelligence Network, which the company expects will benefit from broader professional participation and greater transparency.
Aimwell Partners (OTCID:AIMN), parent of AimwellBio, has published the public contributor page for Christopher A. Jones, PhD, FRSM, showcasing his credentials, institutional affiliation, and verified status within the Federated Health Intelligence Network (FHIN), a named, credentialed professional network supporting AimwellBio’s verified health intelligence platform.
The FHIN Founding Cohort is expanding through peer referral, with Dr. Jones actively introducing additional clinicians and researchers whose contributor pages are expected after onboarding. AimwellBio is also evaluating a potential technology collaboration with Dr. Jones around behavioral engagement and adherence intelligence, but no agreement has been executed and any future collaboration would be announced separately once terms are finalized.
Aimwell Partners (OTC:AIMN), parent of AimwellBio, confirmed it is in advanced discussions with an exclusive, referral-based life sciences capital markets network that links biotech companies with institutional investors, banks and strategic advisors. The introduction came via strategic advisor Christopher A. Jones. Aimwell Partners expects negotiations to conclude next week, when the counterparty and relationship scope are anticipated to be disclosed.
Aimwell Partners (OTC:AIMN) reported that it has entered final-stage negotiations to acquire a portfolio of healthcare-related intellectual property independently valued at approximately $10 million. The IP is described as aligned with Aimwell's strategy of acquiring and developing technology assets to accelerate innovation across the healthcare ecosystem.
Management believes the proposed acquisition could expand Aimwell's portfolio with assets that may support future commercial applications and long-term shareholder value. However, the company emphasizes that the transaction is still contingent on execution of definitive agreements, satisfactory completion of due diligence, and other customary closing conditions, and notes there is no assurance the deal will be completed on the contemplated terms or at all. Aimwell plans to disclose further details on the IP, its strategic role, and commercialization plans if and when definitive agreements are signed.
Aimwell Partners (OTCID:AIMN), parent of AimwellBio, reports active but confidential enterprise-level discussions driven by its credentialed Observer network. Individual professionals are adopting the no-cost Observer tier, prompting institutions to explore broader access to the Federated Health Intelligence Network. Individual subscriptions start at $229 per month.
Aimwell Partners (OTC:AIMN), parent of AimwellBio, launched a public AI intelligence signal feed at aimwellbio.com/signals. The feed exposes 419 regulatory, clinical, and research signals with no login or sales contact, allowing independent verification.
Signals span Phase II/III trials, FDA enforcement and recalls, peer‑reviewed research, and EMA safety/regulatory alerts. AimwellBio differentiates this public layer from its larger subscriber platform, publishes methodology, and offers observer access free to credentialed professionals, with subscriptions from $229/month.
Aimwell Partners (OTC:AIMN), parent of AimwellBio, published Adversarial Validation Standard v1, an open, versioned methodology for validating AI-generated biopharma intelligence. The eight-section framework covers source-trace architecture, four-agent audits, confidence scoring, hallucination containment, governance, and failure-mode correction.
The Standard underpins AimwellBio's Federated Health Intelligence Network, defines verification requirements before AI outputs inform regulatory, clinical, and strategic decisions, and is offered via tiered platform access, including a 60-page reference for subscribers and a 25-page abridged public edition.
Aimwell Partners (OTC PINK:AIMN) is expanding onboarding to AimwellBio Observer, its credentialed health-intelligence network, and has added a one-click LinkedIn signup to speed applications.
Approved professionals receive complimentary access to source-traced biopharma signals, verified public profiles, Signal Lens tools, and a potential path into the Federated Health Intelligence Network.